Kyogo Itoh

14.2k total citations · 1 hit paper
290 papers, 8.0k citations indexed

About

Kyogo Itoh is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kyogo Itoh has authored 290 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 239 papers in Immunology, 123 papers in Oncology and 103 papers in Molecular Biology. Recurrent topics in Kyogo Itoh's work include Immunotherapy and Immune Responses (210 papers), Cancer Immunotherapy and Biomarkers (96 papers) and Immune Cell Function and Interaction (78 papers). Kyogo Itoh is often cited by papers focused on Immunotherapy and Immune Responses (210 papers), Cancer Immunotherapy and Biomarkers (96 papers) and Immune Cell Function and Interaction (78 papers). Kyogo Itoh collaborates with scholars based in Japan, United States and Australia. Kyogo Itoh's co-authors include Akira Yamada, Masanori Noguchi, Shigeki Shichijo, Katsuo Kumagai, Satoko Matsueda, Tetsuro Sasada, Mamoru Harada, Masato Tada, Shuji Hinuma and Nobukazu Komatsu and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Kyogo Itoh

289 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment of plastic petri dishes with fetal calf serum. A simple method for macrophage isolation

1979 450 citations Kyogo Itoh et al. profile →

Peers

Countries citing papers authored by Kyogo Itoh

Since Specialization

Citations

This map shows the geographic impact of Kyogo Itoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyogo Itoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyogo Itoh more than expected).

Fields of papers citing papers by Kyogo Itoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyogo Itoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyogo Itoh. The network helps show where Kyogo Itoh may publish in the future.

Co-authorship network of co-authors of Kyogo Itoh

This figure shows the co-authorship network connecting the top 25 collaborators of Kyogo Itoh. A scholar is included among the top collaborators of Kyogo Itoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyogo Itoh. Kyogo Itoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring the Potential of Humoral Immune Response to Commensal Bifidobacterium as a Biomarker for Human Health, including Both Malignant and Non-Malignant Diseases: A Perspective on Detection Strategies and Future Directions 2024 ·Biomedicines ·Kyogo Itoh, Satoko Matsueda	1
2	Evaluation of the Immunological Response of Childhood Cancer Patients Treated with a Personalized Peptide Vaccine for Refractory Soft Tissue Tumor: A Four-Case Series 2021 ·The Kurume Medical Journal ·Keiko Oda, Yasuhiko Ito, Akira Yamada, Shigeru Yutani, Kyogo Itoh, Shuichi Ozono	0
3	Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11⁺ or ‐A33⁺ allele 2017 ·Cancer Science ·Shinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, Uhi Toh, Masanori Noguchi, Shigeru Yutani, Akira Yamada, Shigeki Shichijo, Teppei Yamada, Shigetaka Suekane, Kouichiro Kawano, (unknown), Tetsuro Sasada, Noboru Hattori, Nobuoki Kohno, Kyogo Itoh	4
4	A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer 2017 ·Cancer Science ·(unknown), (unknown), Satoko Matsueda, Akira Yamada, Shigeki Shichijo, (unknown), (unknown), Shinjiro Sakamoto, Koji Okuda, Kyogo Itoh, Tetsuro Sasada, Shigeru Yutani	34
5	Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients 2016 ·Cancer Science ·Satoru Iwasa, Yasuhide Yamada, Yuji Heike, Hirokazu Shoji, Yoshitaka Honma, Nobukazu Komatsu, Satoko Matsueda, Akira Yamada, (unknown), Rin Yamaguchi, Natsuki Tanaka, Akihiko Kawahara, Masayoshi Kage, Shigeki Shichijo, Tetsuro Sasada, Kyogo Itoh	10
6	An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy 2015 ·Clinical Cancer Research ·Masanori Noguchi, Kazumasa Matsumoto, Hirotsugu Uemura, Gaku Arai, Masatoshi Eto, Seiji Naito, Chikara Οhyama, Yasutomo Nasu, Masatoshi Tanaka, Fukuko Moriya, Shigetaka Suekane, Satoko Matsueda, Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh	49
7	Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients 2015 ·Journal of Immunology Research ·Shigeru Yutani, Kazuomi Ueshima, Kazumichi Abe, Atsushi Ishiguro, Junichi Eguchi, Satoko Matsueda, Nobukazu Komatsu, Shigeki Shichijo, Akira Yamada, Kyogo Itoh, Tetsuro Sasada, Masatoshi Kudo, Masanori Noguchi	15
8	Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer 2014 ·Cancer Immunology Research ·(unknown), Shigeru Yutani, Satoru Motoyama, Takanobu Nomura, Natsuki Tanaka, Akihiko Kawahara, Tomohiko Yamaguchi, Satoko Matsueda, Nobukazu Komatsu, Masatomo Miura, (unknown), Satoshi Hattori, Akira Yamada, Masayoshi Kage, Kyogo Itoh, Yoshito Akagi, Tetsuro Sasada	44
9	Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients’ Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine 2013 ·Evidence-based Complementary and Alternative Medicine ·Shigeru Yutani, Nobukazu Komatsu, Satoko Matsueda, (unknown), (unknown), Akira Yamada, Kyogo Itoh, Tetsuro Sasada	11
10	Identification of peptides applicable as vaccines for HLA‐A26‐positive cancer patients 2009 ·Cancer Science ·(unknown), (unknown), Nobukazu Komatsu, Masanori Noguchi, Shigeki Shichijo, Kyogo Itoh	5
11	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients 2008 ·Oncology Reports ·(unknown), Yoshihiro Komohara, Shigeki Shichijo, Mamoru Harada, Ryuya Yamanaka, Shigeaki Miyamoto, Jun‐ichi Nikawa, Kyogo Itoh, Akira Yamada	15
12	HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma 2007 ·Oncology Reports ·Yoshihiro Komohara, Mamoru Harada, Yuki Ishihara, Shigetaka Suekane, Masanori Noguchi, Akira Yamada, Kei Matsuoka, Kyogo Itoh	22
13	Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients 2006 ·Oncology Reports ·Yi Wang, Mamoru Harada, Hirohisa Yano, Sachiko Ogasawara, Masahiro Tanaka, Akira Yamada, Kyogo Itoh	6
14	Induction of specific anti-tumor responses by CA9 peptide vaccination in patients with metastatic renal cell carcinoma 2006 ·Cancer Research ·Hirotsugu Uemura, (unknown), Motoyoshi Tanaka, Kiyohide Fujimoto, Yoshihiko Hirao, Kyogo Itoh	1
15	Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an IgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis 2006 ·The Journal of Immunology ·Akira Yamada, Hirohisa Yano, (unknown), Takeharu Ono, Tomoko Matsumoto, Kyogo Itoh	7
16	In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide 2004 ·The Journal of Immunology ·Mamoru Harada, (unknown), Satoko Matsueda, Akira Muto, Tatsuya Oda, Yoshiko Iwamoto, Kyogo Itoh	15
17	Biological Activities of the Lectin, Abrin-a, Against Human Lymphocytes and Cultured Leukemic Cell Lines 2000 ·Journal of Hematotherapy & Stem Cell Research ·Sawako Moriwaki, Hideki Ohba, Osamu Nakamura, (unknown), (unknown), Hirohito Tsubouchi, Nobuyuki Yamasaki, Kyogo Itoh	19
18	Interaction of the Hemolytic Lectin, CEL-III, with Cultured Human Leukemic Cell Lines 2000 ·Journal of Hematotherapy & Stem Cell Research ·(unknown), Sawako Moriwaki, Osamu Nakamura, Seiji Yasuda, Makoto Kimura, Nobuyuki Yamasaki, Kyogo Itoh, Hideki Ohba	7
19	Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL 2000 ·The Journal of Immunology ·Masanobu Nakao, Shigeki Shichijo, Toshihiro Imaizumi, Yoshiko Inoue, Kazuko Matsunaga, Akira Yamada, Megumi Kikuchi, Naotake Tsuda, Keisuke Ohta, Shinzo Takamori, Hideaki Yamana, Hiromasa Fujita, Kyogo Itoh	108
20	Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. 1989 ·PubMed ·Masato Yagita, Kyogo Itoh, Mitsuru Tsudo, (unknown), Chris D. Platsoucas, Charles M. Balch, Elizabeth A. Grimm	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact